Amgen, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
The Efficacy and Safety of Adding Methotrexate to Etanercept in Psoriasis
- First Posted Date
- 2009-10-26
- Last Posted Date
- 2013-08-12
- Lead Sponsor
- Amgen
- Target Recruit Count
- 478
- Registration Number
- NCT01001208
ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
- First Posted Date
- 2009-10-26
- Last Posted Date
- 2022-09-21
- Lead Sponsor
- Amgen
- Target Recruit Count
- 1010
- Registration Number
- NCT01001377
- Locations
- 🇬🇧
Research Site, Wolverhampton, United Kingdom
Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With Cystinosis
- Conditions
- Cystinosis
- Interventions
- First Posted Date
- 2009-10-23
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Amgen
- Target Recruit Count
- 43
- Registration Number
- NCT01000961
- Locations
- 🇫🇷
Villeneuve-Lapeyronie Hospital, Montpellier, France
🇺🇸Stanford University Medical School, Stanford, California, United States
🇳🇱Radboud University Nijmegen Medical Center, Nijmegen, Netherlands
A Study of Safety and Efficacy of HPN-100 in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy
- First Posted Date
- 2009-10-21
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Amgen
- Target Recruit Count
- 189
- Registration Number
- NCT00999167
- Locations
- 🇺🇸
The University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸New York Medical College / Westchester Medical Center, Valhalla, New York, United States
🇺🇸University of Maryland, Baltimore, Maryland, United States
Efficacy and Safety of HPN-100 for the Treatment of Adults With Urea Cycle Disorders
- First Posted Date
- 2009-10-09
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Amgen
- Target Recruit Count
- 46
- Registration Number
- NCT00992459
- Locations
- 🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸Maine Medical Center, Portland, Maine, United States
🇺🇸SNBL-Clinical Pharmacology Center, Baltimore, Maryland, United States
Darbepoetin Alfa and Anemia of Cancer
- Conditions
- Anemia of CancerCancerNeoplasmsAnemiaNon-Myeloid MalignanciesCarcinoma
- Interventions
- Biological: darbepoetin alfa
- First Posted Date
- 2009-10-02
- Last Posted Date
- 2014-01-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 287
- Registration Number
- NCT00989092
A Study of Glyceryl Tri-(4-phenylbutyrate) Administered Orally as a Single Dose, and Twice Daily for Seven Consecutive Days to Subjects With Hepatic Impairment With Cirrhosis and to a Control Group
- Conditions
- Urea Cycle DisordersHepatic Encephalopathy
- First Posted Date
- 2009-09-30
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Amgen
- Target Recruit Count
- 32
- Registration Number
- NCT00986895
- Locations
- 🇺🇦
Department of General Surgery #2; Kharkiv State Medical University, Kharkiv, Ukraine
🇺🇦National University of Pharmacy, Kharkiv, Ukraine
Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-steroidal Anti-inflammatory Drug Treatment
- Conditions
- OsteoarthritisRheumatoid ArthritisChronic Low Back PainChronic Regional Pain SyndromeChronic Soft Tissue Pain
- Interventions
- First Posted Date
- 2009-09-25
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Amgen
- Target Recruit Count
- 86
- Registration Number
- NCT00984815
- Locations
- 🇺🇸
Altoona Center for Clinical Research Altoona Arthritis, Duncansville, Pennsylvania, United States
🇺🇸Illinois Bone & Joint Institute, Morton Grove, Illinois, United States
🇺🇸Metroplex Clinical Research Center, Dallas, Texas, United States
Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With Osteoporosis
- Conditions
- OsteopeniaMales With OsteoporosisOsteoporosisLow Bone MassLow Bone Mineral Density
- Interventions
- Other: Placebo
- First Posted Date
- 2009-09-18
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Amgen
- Target Recruit Count
- 242
- Registration Number
- NCT00980174
A Study of Glyceryl Tri-(4-phenylbutyrate) (GT4P)
- First Posted Date
- 2009-09-16
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Amgen
- Target Recruit Count
- 24
- Registration Number
- NCT00977600
- Locations
- 🇺🇦
Medical Sanitary Division #2, Kharkiv, Ukraine